Cargando…

The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions

C-Kit (CD117), the receptor for the stem cell factor, a growth factor for melanocyte migration and proliferation, has shown differential immunostaining in various benign and malignant melanocytic lesions. The purpose of this study is to compare c-Kit immunostaining in benign nevi and in primary and...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilloni, L., Bianco, P., Difelice, E., Cabras, S., Castellanos, M.E., Atzori, L., Ferreli, C., Mulas, P., Nemolato, S., Faa, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284155/
https://www.ncbi.nlm.nih.gov/pubmed/22193299
http://dx.doi.org/10.4081/ejh.2011.e20
_version_ 1782224326594920448
author Pilloni, L.
Bianco, P.
Difelice, E.
Cabras, S.
Castellanos, M.E.
Atzori, L.
Ferreli, C.
Mulas, P.
Nemolato, S.
Faa, G.
author_facet Pilloni, L.
Bianco, P.
Difelice, E.
Cabras, S.
Castellanos, M.E.
Atzori, L.
Ferreli, C.
Mulas, P.
Nemolato, S.
Faa, G.
author_sort Pilloni, L.
collection PubMed
description C-Kit (CD117), the receptor for the stem cell factor, a growth factor for melanocyte migration and proliferation, has shown differential immunostaining in various benign and malignant melanocytic lesions. The purpose of this study is to compare c-Kit immunostaining in benign nevi and in primary and metastatic malignant melanomas, to determine whether c-Kit can aid in the differential diagnosis of these lesions. c-Kit immunostaining was performed in 60 cases of pigmented lesions, including 39 benign nevi (5 blue nevi, 5 intra-dermal nevi, 3 junctional nevi, 15 cases of primary compound nevus, 11 cases of Spitz nevus), 18 cases of primary malignant melanoma and 3 cases of metastatic melanoma. The vast majority of nevi and melanomas examined in this study were positive for c-Kit, with minimal differences between benign and malignant lesions. C-Kit cytoplasmatic immunoreactivity in the intraepidermal proliferating nevus cells, was detected in benign pigmented lesions as well as in malignant melanoma, increasing with the age of patients (P=0.007) in both groups. The patient’s age at presentation appeared to be the variable able to cluster benign and malignant pigmented lesions. The percentage of c-Kit positive intraepidermal nevus cells was better associated with age despite other variables (P=0.014). The intensity and percentage of c-Kit positivity in the proliferating nevus cells in the dermis was significantly increased in malignant melanocytic lesions (P=0.015 and P=0.008) compared to benign lesions (compound melanocytic nevi, Spitz nevi, intradermal nevi, blue nevi). Immunostaning for c-Kit in metastatic melanomas was negative. Interestingly in two cases of melanoma occurring on a pre-existent nevus, the melanoma tumor cells showed strong cytoplasmatic and membranous positivity for c-kit, in contrast with the absence of any immunoreactivity in pre-existent intradermal nevus cells. C-Kit does not appear to be a strong immunohistochemical marker for distinguishing melanoma from melanocytic nevi, if we consider c-Kit expression in intraepidermal proliferating cells. The c-Kit expression in proliferating melanocytes in the dermis could help in the differential diagnosis between a superficial spreading melanoma (with dermis invasion) and a compound nevus or an intradermal nevus. Finally, c-Kit could be a good diagnostic tool for distinguishing benign compound nevi from malignant melanocytic lesions with dermis invasion and to differentiate metastatic melanoma from primary melanoma.
format Online
Article
Text
id pubmed-3284155
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher PAGEPress Publications
record_format MEDLINE/PubMed
spelling pubmed-32841552012-02-23 The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions Pilloni, L. Bianco, P. Difelice, E. Cabras, S. Castellanos, M.E. Atzori, L. Ferreli, C. Mulas, P. Nemolato, S. Faa, G. Eur J Histochem Original Paper C-Kit (CD117), the receptor for the stem cell factor, a growth factor for melanocyte migration and proliferation, has shown differential immunostaining in various benign and malignant melanocytic lesions. The purpose of this study is to compare c-Kit immunostaining in benign nevi and in primary and metastatic malignant melanomas, to determine whether c-Kit can aid in the differential diagnosis of these lesions. c-Kit immunostaining was performed in 60 cases of pigmented lesions, including 39 benign nevi (5 blue nevi, 5 intra-dermal nevi, 3 junctional nevi, 15 cases of primary compound nevus, 11 cases of Spitz nevus), 18 cases of primary malignant melanoma and 3 cases of metastatic melanoma. The vast majority of nevi and melanomas examined in this study were positive for c-Kit, with minimal differences between benign and malignant lesions. C-Kit cytoplasmatic immunoreactivity in the intraepidermal proliferating nevus cells, was detected in benign pigmented lesions as well as in malignant melanoma, increasing with the age of patients (P=0.007) in both groups. The patient’s age at presentation appeared to be the variable able to cluster benign and malignant pigmented lesions. The percentage of c-Kit positive intraepidermal nevus cells was better associated with age despite other variables (P=0.014). The intensity and percentage of c-Kit positivity in the proliferating nevus cells in the dermis was significantly increased in malignant melanocytic lesions (P=0.015 and P=0.008) compared to benign lesions (compound melanocytic nevi, Spitz nevi, intradermal nevi, blue nevi). Immunostaning for c-Kit in metastatic melanomas was negative. Interestingly in two cases of melanoma occurring on a pre-existent nevus, the melanoma tumor cells showed strong cytoplasmatic and membranous positivity for c-kit, in contrast with the absence of any immunoreactivity in pre-existent intradermal nevus cells. C-Kit does not appear to be a strong immunohistochemical marker for distinguishing melanoma from melanocytic nevi, if we consider c-Kit expression in intraepidermal proliferating cells. The c-Kit expression in proliferating melanocytes in the dermis could help in the differential diagnosis between a superficial spreading melanoma (with dermis invasion) and a compound nevus or an intradermal nevus. Finally, c-Kit could be a good diagnostic tool for distinguishing benign compound nevi from malignant melanocytic lesions with dermis invasion and to differentiate metastatic melanoma from primary melanoma. PAGEPress Publications 2011-06-07 /pmc/articles/PMC3284155/ /pubmed/22193299 http://dx.doi.org/10.4081/ejh.2011.e20 Text en ©Copyright L. Pilloni et al., 2011 This work is licensed under a Creative Commons Attribution 3.0 License (by-nc 3.0). Licensee PAGEPress, Italy
spellingShingle Original Paper
Pilloni, L.
Bianco, P.
Difelice, E.
Cabras, S.
Castellanos, M.E.
Atzori, L.
Ferreli, C.
Mulas, P.
Nemolato, S.
Faa, G.
The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions
title The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions
title_full The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions
title_fullStr The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions
title_full_unstemmed The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions
title_short The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions
title_sort usefulness of c-kit in the immunohistochemical assessment of melanocytic lesions
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284155/
https://www.ncbi.nlm.nih.gov/pubmed/22193299
http://dx.doi.org/10.4081/ejh.2011.e20
work_keys_str_mv AT pillonil theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT biancop theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT difelicee theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT cabrass theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT castellanosme theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT atzoril theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT ferrelic theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT mulasp theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT nemolatos theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT faag theusefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT pillonil usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT biancop usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT difelicee usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT cabrass usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT castellanosme usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT atzoril usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT ferrelic usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT mulasp usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT nemolatos usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions
AT faag usefulnessofckitintheimmunohistochemicalassessmentofmelanocyticlesions